Literature DB >> 17191095

Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition.

J Cory Kalvass1, Gary M Pollack.   

Abstract

PURPOSE: Unexpected and complex experimental observations related to efflux transport have been reported in the literature. This work was conducted to develop relationships for efflux activity (PS(efflux)) as a function of commonly studied kinetic parameters [permeability-surface area product (PS), efflux ratio (ER), degree of efflux inhibition (phi(i)), 50% inhibitory concentration (IC(50)), and Michaelis-Menten constant (K(m))].
METHODS: A three-compartment model (apical, cellular, and basolateral) was used to derive flux equations relating the initial rate of flux and steady-state mass transfer in the presence or absence of active efflux. Various definitions of efflux ratio (ER) were examined in terms of permeability-surface area products. The efflux activity (PS(efflux)) was expressed in terms of ER and PS. The relationships between PS(efflux) and PS, ER, phi(i), IC(50), and K(m) were solved mathematically. Simulations and examples from the literature were used to illustrate the resulting mathematical relationships.
RESULTS: The relationships derived according to a three-compartment model differed fundamentally from commonly accepted approaches for determining PS(efflux), phi(i), IC(50) and K(m). Based on the model assumptions and mathematical derivations, currently used mathematical relationships erroneously imply that efflux activity is proportional to change in PS (i.e., flux or P(app)) and thus underestimate PS(efflux) and phi(i,) and overestimate IC(50) and K(m).
CONCLUSIONS: An understanding of the relationship between efflux inhibition and kinetic parameters is critical for appropriate data interpretation, standardization in calculating and expressing the influence of efflux transport, and predicting the clinical significance of efflux inhibition.

Mesh:

Substances:

Year:  2006        PMID: 17191095     DOI: 10.1007/s11095-006-9135-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

Review 1.  Transporters and drug therapy: implications for drug disposition and disease.

Authors:  Richard H Ho; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2005-09       Impact factor: 6.875

2.  The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.

Authors:  Thuy Thanh Tran; Aditya Mittal; Tanya Aldinger; Joseph W Polli; Andrew Ayrton; Harma Ellens; Joe Bentz
Journal:  Biophys J       Date:  2004-10-22       Impact factor: 4.033

3.  Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Authors:  Kelly M Mahar Doan; Joan E Humphreys; Lindsey O Webster; Stephen A Wring; Larry J Shampine; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

4.  Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.

Authors:  Y Adachi; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

5.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.

Authors:  M Yamazaki; W E Neway; T Ohe; I Chen; J F Rowe; J H Hochman; M Chiba; J H Lin
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

6.  Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice.

Authors:  J Cory Kalvass; Candace L Graff; Gary M Pollack
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

Review 7.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

Authors:  Hilary Thomas; Helen M Coley
Journal:  Cancer Control       Date:  2003 Mar-Apr       Impact factor: 3.302

8.  Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.

Authors:  Jiunn H Lin
Journal:  Adv Drug Deliv Rev       Date:  2003-01-21       Impact factor: 15.470

9.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

Authors:  C M F Kruijtzer; J H Beijnen; H Rosing; W W ten Bokkel Huinink; M Schot; R C Jewell; E M Paul; J H M Schellens
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

10.  Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy.

Authors:  Todd Hulgan; John P Donahue; Charlene Hawkins; Derya Unutmaz; Richard T D'Aquila; Stephen Raffanti; Fred Nicotera; Peter Rebeiro; Husamettin Erdem; Melissa Rueff; David W Haas
Journal:  J Acquir Immune Defic Syndr       Date:  2003-10-01       Impact factor: 3.731

View more
  30 in total

Review 1.  Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.

Authors:  Loqman A Mohamed; Shashirekha Markandaiah; Silvia Bonanno; Piera Pasinelli; Davide Trotti
Journal:  AAPS J       Date:  2017-08-04       Impact factor: 4.009

2.  The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models.

Authors:  Emile P Chen; Guoying Tai; Harma Ellens
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

3.  Compartmental models for apical efflux by P-glycoprotein--part 1: evaluation of model complexity.

Authors:  Swati Nagar; Jalia Tucker; Erica A Weiskircher; Siddhartha Bhoopathy; Ismael J Hidalgo; Ken Korzekwa
Journal:  Pharm Res       Date:  2013-09-10       Impact factor: 4.200

4.  Structural and conformational determinants of macrocycle cell permeability.

Authors:  Björn Over; Pär Matsson; Christian Tyrchan; Per Artursson; Bradley C Doak; Michael A Foley; Constanze Hilgendorf; Stephen E Johnston; Maurice D Lee; Richard J Lewis; Patrick McCarren; Giovanni Muncipinto; Ulf Norinder; Matthew W D Perry; Jeremy R Duvall; Jan Kihlberg
Journal:  Nat Chem Biol       Date:  2016-10-17       Impact factor: 15.040

5.  Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).

Authors:  Anita Kort; Selvi Durmus; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Journal:  Pharm Res       Date:  2015-01-08       Impact factor: 4.200

Review 6.  Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels.

Authors:  Kyoung Ah Min; Xinyuan Zhang; Jing-yu Yu; Gus R Rosania
Journal:  Biopharm Drug Dispos       Date:  2013-12-10       Impact factor: 1.627

7.  Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OSTα/β).

Authors:  Melina M Malinen; Antti Kauttonen; James J Beaudoin; Noora Sjöstedt; Paavo Honkakoski; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2018-12-14       Impact factor: 4.939

Review 8.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

Review 9.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

Review 10.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.